Skip to main content
Premium Trial:

Request an Annual Quote

Burzynski Using UAB for Bioinformatics

NEW YORK (GenomeWeb News) – The Burzynski Research Institute has struck a research agreement with the University of Alabama at Birmingham, under which the school will provide bioinformatics and data management support for the company's glioma treatment studies.

BRI, a Houston-based company focused on using genomics and epigenomics for cancer studies, said that UAB's Biostatistics and Bioinformatics Shared Facility (BBSF) will support its Phase I and Phase II protocol studies of Antineoplaston therapy, a treatment for gliomas.

BBSF will support BRI's statistical analysis development in a variety of ways, including database design, data receipt, management, long-term storage, implementing quality assurance plans, and data quality and reporting. The facility is developing new methodologies and approaches for incorporating the results of statistical analyses into reports, presentations, and publications, and systems for long-term data storage, backup, and retrieval.

BBSF already has helped BRI develop Phase II and Phase III protocol studies of Antineoplaston therapy for glioma, which is currently being submitted to the US Food and Drug Administration for approval, the company said.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.